文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

达巴万星治疗金黄色葡萄球菌菌血症:DOTS随机临床试验

Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-08-13

这项在美加23个中心开展的开放标签、评估者设盲随机试验纳入200例复杂金黄色葡萄球菌菌血症成人患者,比较达巴万星与标准静脉治疗。达巴万星在第70天结局优劣排序上未优于标准治疗(概率47.7%,95%CI 39.8%至55.7%),临床疗效符合非劣效标准(差值1.0%,95%CI -11.5%至13.5%)。

要点

  • 达巴万星第70天获得更优结局的概率为47.7%(95%CI 39.8%至55.7%),未达 superiority。
  • 临床疗效达巴万星组73/100 vs 标准治疗组72/100,差值1.0%(95%CI -11.5%至13.5%),符合非劣效。
  • 严重不良事件达巴万星组40/100 vs 标准治疗组34/100,治疗相关不良事件两组均不常见。

核心结论

  • 在实现血培养清除的复杂金黄色葡萄球菌菌血症成人患者中,达巴万星按结局优劣排序未优于标准治疗。
  • 结合其他疗效和安全性结局,这些发现可能有助于指导达巴万星在临床实践中的使用。

研究设计与样本

  • 开放标签、评估者设盲、随机临床试验,于2021年4月至2023年12月在美国22个和加拿大1个共23个医疗中心开展。
  • 参与者随访持续70天(骨髓炎参与者180天),末次随访日期为2023年12月1日。
  • 纳入在初始抗菌治疗至少72小时但不超过10天后实现血培养清除的住院成人复杂金黄色葡萄球菌菌血症患者。
  • 排除中枢神经系统感染、留置感染性假体材料、左侧心内膜炎或严重免疫抑制者。
  • 共随机200例:达巴万星组100例,标准治疗组100例;平均(SD)年龄56(16.2)岁,女性62例(31%)。

主要发现

  • 167例(84%)存活至第70天并接受疗效评估;无第70天疗效评估者按临床失败处理。
  • 达巴万星相较于标准治疗获得更理想第70天结局的概率为47.7%(95%CI 39.8%至55.7%)。
  • 临床疗效:达巴万星组73/100 vs 标准治疗组72/100,差值1.0%(95%CI -11.5%至13.5%),符合非劣效标准。
  • 严重不良事件:达巴万星组40/100 vs 标准治疗组34/100;治疗相关不良事件两组均不常见。

关键数值与推荐

  • 主要结局为第70天结局优劣排序(DOOR),包含临床成功、感染并发症、安全性并发症、死亡率和健康相关生活质量5个组分。
  • 优效性判定标准:达巴万星具有更优DOOR的概率的95%CI下限>50%。
  • 临床疗效非劣效界值为20%。

临床怎么用

  • 作者认为,结合其他疗效和安全性结局,这些发现可能有助于指导达巴万星在临床实践中的使用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Dalbavancin is a long-acting intravenous lipoglycopeptide that may be effective for treatment of complicated Staphylococcus aureus bacteremia without requiring long-term intravenous access. OBJECTIVE: To evaluate the efficacy and safety of dalbavancin vs standard therapy for completion of treatment of complicated S aureus bacteremia. DESIGN, SETTING, AND PARTICIPANTS: Open-label, assessor-masked, randomized clinical trial conducted from April 2021 to December 2023 at 23 medical centers in the US (n = 22) and Canada (n = 1). Participant follow-up lasted 70 days (180 days for participants with osteomyelitis); date of final follow-up was December 1, 2023. Hospitalized adults with complicated S aureus bacteremia who achieved blood culture clearance following at least 72 hours but no more than 10 days of initial antibacterial therapy were included. Participants were excluded if they had central nervous system infection, retained infected prosthetic material, left-sided endocarditis, or severe immune compromise. INTERVENTIONS: Participants were randomly assigned to receive either 2 doses of intravenous dalbavancin (n = 100; 1500 mg on days 1 and 8) or 4 to 8 total weeks of standard intravenous therapy (n = 100; cefazolin or antistaphylococcal penicillin if methicillin susceptible; vancomycin or daptomycin if methicillin resistant). MAIN OUTCOMES AND MEASURES: The primary outcome was the desirability of outcome ranking (DOOR) at day 70, which involved 5 components (clinical success, infectious complications, safety complications, mortality, and health-related quality of life) and was assessed for superiority (achieved if the 95% CI for the probability of dalbavancin having a superior DOOR was >50%). Secondary outcomes included clinical efficacy at day 70 (prespecified noninferiority margin of 20%) and safety. RESULTS: Of 200 participants randomized (mean [SD] age, 56 [16.2] years; 62 females [31%]), 167 (84%) survived to day 70 and had an efficacy assessment. Participants without a day 70 efficacy assessment were treated as clinical failures in the analyses. The probability of a more desirable day 70 outcome with dalbavancin vs standard therapy was 47.7% (95% CI, 39.8% to 55.7%). Regarding secondary outcomes, clinical efficacy was documented in 73 of 100 for dalbavancin and 72 of 100 for standard therapy (difference, 1.0% [95% CI, -11.5% to 13.5%]), meeting the noninferiority criterion. Serious adverse events were reported in 40 of 100 participants who received dalbavancin and 34 of 100 participants who received standard therapy; treatment-related adverse events were uncommon in both groups. CONCLUSIONS AND RELEVANCE: Among adult participants with complicated S aureus bacteremia who achieved blood culture clearance, dalbavancin was not superior to standard therapy by desirability of outcome ranking. When considered with other efficacy and safety outcomes these findings may help inform use of dalbavancin in clinical practice. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04775953.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Turner NA, Hamasaki T, Doernberg SB, et al. Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial. JAMA. 2025. PMID: 40802264. doi:10.1001/jama.2025.12543

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。